The Optimal Injection Site for a 3D Guided Inferior Alveolar Nerve Block Device (IANBD)

Launched by BOSTON UNIVERSITY · Nov 4, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "The Optimal Injection Site for a 3D Guided Inferior Alveolar Nerve Block Device (IANBD)," is exploring a new way to provide anesthesia for dental procedures involving the lower jaw. Traditional methods of numbing this area can be tricky and may not always work well, leading to discomfort for patients. This trial will test a new device that uses 3D imaging to precisely guide the injection of anesthesia, aiming to improve the success rate on the first try and reduce pain and tissue damage.

To participate in this trial, individuals must be patients at Boston University’s dental school and need non-surgical endodontic therapy (a common dental procedure) on specific teeth in the lower jaw. They should be generally healthy and have certain dental conditions that allow for treatment. Participants can expect to receive anesthesia through this new guided method, and the trial will help researchers learn about its safety and effectiveness. It's important to note that not everyone can join; for example, individuals with allergies to specific medications or those who are pregnant won't be eligible.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient of Henry M. Goldman School of Dentistry (GSDM)
• • Medical History indicating American Society of Anesthesiology (ASA)1
• • Need Non-surgical Endodontic Therapy on Mandibular Molar or Premolar
• • Asymptomatic pulpal diagnosis (normal, necrotic, asymptomatic irreversible pulpitis, retreatment with no symptoms)
• • The quadrant to be treated must have at least 3 vital teeth.
• • Going to receive a CBCT required for clinical purposes
• • Must be willing to receive guided IANB
• Exclusion Criteria:
• • Allergy to lidocaine or articaine
• • Resin allergy
• • Normal teeth unresponsive to thermal testing (ie calcified chamber)
• • Prior jaw surgery
• • Currently pregnant